vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and VICOR CORP (VICR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $113.0M, roughly 1.5× VICOR CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 20.2%). Over the past eight quarters, VICOR CORP's revenue compounded faster (14.7% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
ESPR vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $113.0M |
| Net Profit | — | $20.7M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 59.7% |
| Net Margin | — | 18.3% |
| Revenue YoY | 143.7% | 20.2% |
| Net Profit YoY | — | 713.9% |
| EPS (diluted) | $0.32 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $168.4M | $107.3M | ||
| Q3 25 | $87.3M | $110.4M | ||
| Q2 25 | $82.4M | $96.0M | ||
| Q1 25 | $65.0M | $94.0M | ||
| Q4 24 | $69.1M | $96.2M | ||
| Q3 24 | $51.6M | $93.2M | ||
| Q2 24 | $73.8M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | $-31.3M | $28.3M | ||
| Q2 25 | $-12.7M | $41.2M | ||
| Q1 25 | $-40.5M | $2.5M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | $-29.5M | $11.6M | ||
| Q2 24 | $-61.9M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 57.5% | ||
| Q2 25 | — | 95.9% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | — | 52.4% | ||
| Q3 24 | — | 49.1% | ||
| Q2 24 | — | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 50.6% | 14.6% | ||
| Q3 25 | -11.4% | 18.9% | ||
| Q2 25 | 8.6% | 47.3% | ||
| Q1 25 | -34.0% | -0.2% | ||
| Q4 24 | -6.4% | 9.6% | ||
| Q3 24 | -31.0% | 5.8% | ||
| Q2 24 | 3.5% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | — | 43.4% | ||
| Q3 25 | -35.9% | 25.6% | ||
| Q2 25 | -15.4% | 42.9% | ||
| Q1 25 | -62.2% | 2.7% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | -57.2% | 12.4% | ||
| Q2 24 | -83.9% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.32 | $1.01 | ||
| Q3 25 | $-0.16 | $0.63 | ||
| Q2 25 | $-0.06 | $0.91 | ||
| Q1 25 | $-0.21 | $0.06 | ||
| Q4 24 | $-0.14 | $0.24 | ||
| Q3 24 | $-0.15 | $0.26 | ||
| Q2 24 | $-0.33 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $404.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $754.1M |
| Total Assets | $465.9M | $804.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $167.9M | $402.8M | ||
| Q3 25 | $92.4M | $362.4M | ||
| Q2 25 | $86.1M | $338.5M | ||
| Q1 25 | $114.6M | $296.1M | ||
| Q4 24 | $144.8M | $277.3M | ||
| Q3 24 | $144.7M | $267.6M | ||
| Q2 24 | $189.3M | $251.9M |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $-302.0M | $711.6M | ||
| Q3 25 | $-451.4M | $630.1M | ||
| Q2 25 | $-433.5M | $608.6M | ||
| Q1 25 | $-426.2M | $580.3M | ||
| Q4 24 | $-388.7M | $570.1M | ||
| Q3 24 | $-370.2M | $554.6M | ||
| Q2 24 | $-344.2M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $465.9M | $785.8M | ||
| Q3 25 | $364.0M | $710.2M | ||
| Q2 25 | $347.1M | $693.5M | ||
| Q1 25 | $324.0M | $665.0M | ||
| Q4 24 | $343.8M | $641.1M | ||
| Q3 24 | $314.1M | $632.8M | ||
| Q2 24 | $352.3M | $613.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $15.7M | ||
| Q3 25 | $-4.3M | $38.5M | ||
| Q2 25 | $-31.4M | $65.2M | ||
| Q1 25 | $-22.6M | $20.1M | ||
| Q4 24 | $-35.0M | $10.1M | ||
| Q3 24 | $-35.3M | $22.6M | ||
| Q2 24 | $-7.2M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $34.5M | ||
| Q2 25 | — | $59.0M | ||
| Q1 25 | — | $15.6M | ||
| Q4 24 | — | $8.4M | ||
| Q3 24 | $-35.5M | $14.1M | ||
| Q2 24 | $-7.3M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.5% | ||
| Q3 25 | — | 31.2% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 8.7% | ||
| Q3 24 | -68.7% | 15.2% | ||
| Q2 24 | -9.9% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.2% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | 0.0% | 6.5% | ||
| Q1 25 | 0.0% | 4.8% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.3% | 9.1% | ||
| Q2 24 | 0.1% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.58× | ||
| Q1 25 | — | 7.93× | ||
| Q4 24 | — | 0.99× | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
